Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Research

Seasonally calm start to the year

By Antti SiltanenAnalyst
Nexstim
Download report (PDF)

Nexstim published its Q1 business update on Friday. The company reported that it delivered two NBS systems during the period. Deliveries were slightly below our expectations in a seasonally slow start to the year. Based on the new data, we are modestly lowering our forecasts for the coming years. There have been no material changes in the valuation picture of the share. The stock is cheaply priced, but the risks are also elevated due to low visibility and a tight financial situation.

Login required

This content is only available for logged in users

Create account

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more on company page

Key Estimate Figures28.04.2024

202324e25e
Revenue7.28.310.8
growth-%-23.9 %14.8 %30.3 %
EBIT (adj.)-1.2-0.70.6
EBIT-% (adj.)-16.9 %-8.5 %5.4 %
EPS (adj.)-0.18-0.110.07
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.209.2
EV/EBITDAneg.1,022.883.9

Forum discussions

Is the advent calendar going to be empty today as well
yesterday
by Apesor
0
Tomorrow is a good day to announce the final Sinaptica deal. In the letter of intent, it was stated that the intention is to sign the definitive...
12/18/2025, 9:21 PM
by Jatast
12
Just earlier, the CEO stated very clearly that “We continue to report the hardware volumes delivered to all our customers (thus including hardware...
12/18/2025, 12:44 PM
by SentinVenyttäjä
14
Brainlab’s and Sinaptica’s transactions are not itemized and are aimed to be reported. This means there might be hidden equipment sales. At ...
12/18/2025, 11:34 AM
by Tee
2
The company is at the root of such a big healthcare megatrend (e.g., treatment of depression) and the scalable market is global, so there are...
12/18/2025, 10:08 AM
by Prototyping
11
The business was similar when the stock traded at 3 euros, so it might even be smart to lighten up? Always operating at a loss and very small...
12/18/2025, 7:13 AM
by Pyylevä
0
In these companies, you always have to wait for the earnings report for the truth to be revealed. Unless there’s a warning before that. It would...
12/18/2025, 7:09 AM
by QRB Strong buy
14
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.